Patient P-01756

Synthetic patientNBL-101 · Day 108 · 45–54 · F · baseline S03Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Favorable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Favorable

Discontinuation risk

10%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S03
Day 28 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 28.

Primary contributors, last 14 days

Inflammatory activity-8
GI instability-4
Treatment adherence+4
Nutritional resilience-2
Toxicity-2

What helped?

No interventions yet.

LIFE OS recommendation

No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

12.2/100

worsening · +1.9 vs previous 14 d

Toxicity

Blood

18.7/100

improving · -10.3 vs previous 14 d

Sleep quality

Wearable

66.2/100

stable · +0.8 vs previous 14 d

Energy level

Daily log

7.3/10

improving · +0.5 vs previous 14 d

Stress level

Daily log

3.4/10

improving · -0.4 vs previous 14 d

Steps

Wearable

4,340

improving · +246 vs previous 14 d

Adherence

Companion

92.6 %

stable · +1.8 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 83 from the failing basin, 17 from restoration.

Would help

No untried action with strong evidence. Compose one from primitives.

Would not help

Nothing clearly counter-productive in the record.

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+1.9no signal · 38%
Histamine load
+1.8no signal · 40%
Spicy / capsaicin
-1no signal · 21%
Alcohol
+0.9no signal · 19%
Simple carbohydrates
-0.5no signal · 15%
Insoluble fibre
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted

DNA

Fictional pharmacogenomic panel

DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3.6 · butyrate capacity 79/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 47 ms
Sleep: 7.5 h
Steps: 3,622
Resting HR: 61 bpm

Daily log: GI score 12, nutritional resilience 70, adherence 93.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01430	45%	S05	CR-01	improved	54
P-01724	44%	S10	DT-01	improved	63
P-01804	40%	S19	AD-05	improved	61
P-01555	39%	S06	GI-04	improved	56
P-01346	38%	S12	DT-01	improved	52
P-01385	38%	S06	HY-01	improved	50
P-01593	38%	S10	HY-01	improved	56
P-01455	37%	S01	GI-04	improved	61
P-01571	37%	S13	SC-12	improved	57
P-01752	36%	S20	DT-01	improved	50
P-01861	36%	S12	HY-01	improved	47
P-01374	35%	S08	HY-01	improved	49